SCHEMBL15075720

SCHEMBL15075720

CC1CC=CC=C1c1nc2ccccc2o1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.48
CHRM4 P08173 1/20 0.48
CHRM5 P08912 1/20 0.48
CHRM1 P11229 1/20 0.48
CHRM3 P20309 1/20 0.48
NPC1 O15118 9/20 0.43
ALDH1A1 P00352 8/20 0.43
RAB9A P51151 7/20 0.43
HPGD P15428 7/20 0.43
HSD17B10 Q99714 6/20 0.43
KDM4E B2RXH2 6/20 0.43
SMN1; SMN2 Q16637 5/20 0.43
TP53 P04637 4/20 0.43
MAPT P10636 4/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
PKM P14618 2/20 0.43
HCRTR1 O43613 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12355588 0.73 NPC1 (0.49) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL29531707 0.73 NPC1 (0.69) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL824375 0.73 NPC1 (0.69) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL6742287 0.71 CHRM2 (0.45) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL12687385 0.70 CHRM2 (0.47) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL11800006 0.68 ALDH1A1 (0.46) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL8076439 0.68 NPC1 (0.43) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL7804226 0.68 NPC1 (0.44) NPC1ALDH1A1RAB9AHPGDHSD17B10
Anthracene SCHEMBL29003509 0.66 NPC1 (0.66) NPC1ALDH1A1RAB9AHPGDHSD17B10
SCHEMBL31170 0.66 NPC1 (0.81) NPC1ALDH1A1RAB9AHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3184527-A1 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL Hydra Biosciences, Inc. (US) 2017-06-28 EP disclosed
EP-2170309-B1 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL HYDRA BIOSCIENCES INC (US) 2016-10-26 EP disclosed
US-20130165427-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES HYDRA BIOSCIENCES, INC. (US) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165427-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES ELANE, CASP3, MMP8 CHRM2 4151/4885CHRM4 3377/4885CHRM5 3712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.